NYSE:AZNAstraZeneca Stock Price, Forecast & News

$54.72

-0.44 (-0.80 %)

(As of 06/2/2020 04:00 PM ET)

Add

Compare

Today's Range

$54.10

Now: $54.72▼

$54.74

50-Day Range

$44.66

MA: $52.30▼

$55.31

52-Week Range

$36.15

Now: $54.72▼

$57.44

Volume4.28 million shs

Average Volume4.43 million shs

Market Capitalization$143.61 billion

P/E Ratio92.75

Dividend Yield3.37%

Beta0.57

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.

Beat the Market (BTM) Rank^™

2.2 Analyst's Opinion

Consensus Rating
AstraZeneca has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 5 buy ratings, 2 hold ratings, and 2 sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $60.00, AstraZeneca has a potential upside of 9.6% from its current price of $54.72.
Amount of Analyst Coverage
AstraZeneca has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.9 Community Rank

Outperform Votes
AstraZeneca has received 745 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
AstraZeneca has received 1,232 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
AstraZeneca has received 62.32% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about AstraZeneca and other stocks. Vote “Outperform” if you believe AZN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AZN will underperform the S&P 500 over the long term. You may vote once every thirty days.

2.5 Dividend Strength

Dividend Leadership
AstraZeneca is a leading dividend payer. It pays a dividend yield of 3.37%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
AstraZeneca does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of AstraZeneca is 106.29 %. Payout ratios above 75% are not desirable because they may not be sustainable.
Dividend Sustainability
Based on earnings estimates, AstraZeneca will have a dividend payout ratio of 71.54 % next year. This indicates that AstraZeneca will be able to sustain or increase its dividend.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, AstraZeneca insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 16.84% of the stock of AstraZeneca is held by institutions.

1.3 Earnings and Valuation

Earnings Growth
Earnings for AstraZeneca are expected to grow by 28.71% in the coming year, from $2.02 to $2.60 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of AstraZeneca is 92.75, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 15.75.
Price to Earnings Ratio vs. Sector
The P/E ratio of AstraZeneca is 92.75, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 25.47.
Price to Earnings Growth Ratio
AstraZeneca has a PEG Ratio of 1.66. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
AstraZeneca has a P/B Ratio of 9.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.56 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NYSE

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNYSE:AZN

Previous Symbol

CUSIPN/A

CIK901832

Webwww.astrazeneca.com

Phone44-20-3749-5000

Debt

Debt-to-Equity Ratio1.32

Current Ratio0.75

Quick Ratio0.57

Price-To-Earnings

Trailing P/E Ratio92.75

Forward P/E Ratio27.09

P/E Growth1.66

Sales & Book Value

Annual Sales$24.38 billion

Price / Sales5.89

Cash Flow$3.17 per share

Price / Cash Flow17.24

Book Value$5.56 per share

Price / Book9.84

Profitability

EPS (Most Recent Fiscal Year)$1.75

Net Income$1.34 billion

Net Margins5.94%

Return on Equity33.97%

Return on Assets7.88%

Miscellaneous

Employees64,400

Outstanding Shares2,624,374,000

Market Cap$143.61 billion

Next Earnings Date7/23/2020 (Estimated)

OptionableOptionable

Receive AZN News and Ratings via Email

Sign-up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter.

AstraZeneca (NYSE:AZN) Frequently Asked Questions

How has AstraZeneca's stock been impacted by COVID-19 (Coronavirus)?

AstraZeneca's stock was trading at $44.58 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AZN shares have increased by 22.7% and is now trading at $54.72. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of AstraZeneca?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There are currently 2 sell ratings, 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for AstraZeneca.

When is AstraZeneca's next earnings date?

AstraZeneca is scheduled to release its next quarterly earnings announcement on Thursday, July 23rd 2020. View our earnings forecast for AstraZeneca.

How were AstraZeneca's earnings last quarter?

AstraZeneca plc (NYSE:AZN) issued its earnings results on Wednesday, April, 29th. The company reported $0.53 EPS for the quarter, beating the Zacks' consensus estimate of $0.47 by $0.06. The firm earned $6.35 billion during the quarter, compared to the consensus estimate of $5.95 billion. AstraZeneca had a net margin of 5.94% and a return on equity of 33.97%. The company's revenue for the quarter was up 16.3% on a year-over-year basis. During the same period in the previous year, the firm posted $0.89 EPS. View AstraZeneca's earnings history.

How often does AstraZeneca pay dividends? What is the dividend yield for AstraZeneca?

AstraZeneca announced a semi-annual dividend on Tuesday, February 18th. Shareholders of record on Friday, February 28th will be given a dividend of $0.95 per share on Monday, March 30th. This represents a dividend yield of 2.8%. The ex-dividend date of this dividend is Thursday, February 27th. View AstraZeneca's dividend history.

When did AstraZeneca's stock split? How did AstraZeneca's stock split work?

Shares of AstraZeneca split on Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly created shares were issued to shareholders after the market closes on Friday, July 24th 2015. An investor that had 100 shares of AstraZeneca stock prior to the split would have 200 shares after the split.

What price target have analysts set for AZN?

9 analysts have issued twelve-month target prices for AstraZeneca's stock. Their forecasts range from $55.00 to $65.00. On average, they anticipate AstraZeneca's stock price to reach $60.00 in the next twelve months. This suggests a possible upside of 9.6% from the stock's current price. View analysts' price targets for AstraZeneca.

Has AstraZeneca been receiving favorable news coverage?

Media coverage about AZN stock has been trending very negative this week, according to InfoTrie. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. AstraZeneca earned a media sentiment score of -3.5 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutAstraZeneca.

Who are some of AstraZeneca's key competitors?

Some companies that are related to AstraZeneca include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Pfizer (PFE), Merck & Co., Inc. (MRK), Novartis (NVS), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), Eli Lilly And Co (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Sanofi (SNY), GlaxoSmithKline (GSK), Commonwealth Bank of Australia (CSLLY), Celgene (CELG) and Vertex Pharmaceuticals (VRTX). View all competitors.

What other stocks do shareholders of AstraZeneca own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AstraZeneca investors own include Pfizer (PFE), AbbVie (ABBV), AT&T (T), Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), NVIDIA (NVDA), Alibaba Group (BABA), Cisco Systems (CSCO), Bank of America (BAC) and Johnson & Johnson (JNJ).

Who are AstraZeneca's key executives?

AstraZeneca's management team includes the following people:

Mr. Pascal Soriot, CEO & Exec. Director (Age 60)
Mr. Marc Dunoyer, CFO & Exec. Director (Age 67)
Ms. Pam P. Cheng, Exec. Vice-Pres of Operations & Information Technology (Age 48)
Thomas Kudsk Larsen, Head of Investor Relations
Mr. Jefrey Pott, Gen. Counsel

What is AstraZeneca's stock symbol?

AstraZeneca trades on the New York Stock Exchange (NYSE) under the ticker symbol "AZN."

Who are AstraZeneca's major shareholders?

AstraZeneca's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Wellington Management Group LLP (2.57%), Primecap Management Co. CA (2.16%), Jennison Associates LLC (1.48%), Capital International Investors (1.08%), Fisher Asset Management LLC (0.63%) and Invesco Ltd. (0.41%). View institutional ownership trends for AstraZeneca.

Which institutional investors are selling AstraZeneca stock?

AZN stock was sold by a variety of institutional investors in the last quarter, including Primecap Management Co. CA, Russell Investments Group Ltd., Eaton Vance Management, Magnetar Financial LLC, Cookson Peirce & Co. Inc., Voloridge Investment Management LLC, Waddell & Reed Financial Inc., and Parametric Portfolio Associates LLC. View insider buying and selling activity for AstraZeneca.

Which institutional investors are buying AstraZeneca stock?

AZN stock was acquired by a variety of institutional investors in the last quarter, including Capital International Investors, BlackRock Inc., Wellington Management Group LLP, Jennison Associates LLC, Invesco Ltd., Capital World Investors, Sphera Funds Management LTD., and Nuveen Asset Management LLC. View insider buying and selling activity for AstraZeneca.

How do I buy shares of AstraZeneca?

Shares of AZN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AstraZeneca's stock price today?

One share of AZN stock can currently be purchased for approximately $54.72.

How big of a company is AstraZeneca?

AstraZeneca has a market capitalization of $143.61 billion and generates $24.38 billion in revenue each year. The company earns $1.34 billion in net income (profit) each year or $1.75 on an earnings per share basis. AstraZeneca employs 64,400 workers across the globe.

What is AstraZeneca's official website?

The official website for AstraZeneca is www.astrazeneca.com.

How can I contact AstraZeneca?

AstraZeneca's mailing address is 1 FRANCIS CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE X0, CB2 0AA. The company can be reached via phone at 44-20-3749-5000 or via email at [email protected]

This page was last updated on 6/2/2020 by MarketBeat.com Staff